BR112017016465A2 - heterocyclic compound and pharmaceutical composition comprising it - Google Patents
heterocyclic compound and pharmaceutical composition comprising itInfo
- Publication number
- BR112017016465A2 BR112017016465A2 BR112017016465-5A BR112017016465A BR112017016465A2 BR 112017016465 A2 BR112017016465 A2 BR 112017016465A2 BR 112017016465 A BR112017016465 A BR 112017016465A BR 112017016465 A2 BR112017016465 A2 BR 112017016465A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- heterocyclic compound
- heterocyclic
- compound
- pharmaceutical
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0017339 | 2015-02-04 | ||
KR20150017339 | 2015-02-04 | ||
PCT/KR2016/001133 WO2016126085A2 (en) | 2015-02-04 | 2016-02-02 | Heterocyclic compound and pharmaceutical composition comprising same |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017016465A2 true BR112017016465A2 (en) | 2018-06-19 |
BR112017016465B1 BR112017016465B1 (en) | 2023-11-14 |
Family
ID=56564854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017016465-5A BR112017016465B1 (en) | 2015-02-04 | 2016-02-02 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT |
Country Status (14)
Country | Link |
---|---|
US (3) | US10227328B2 (en) |
EP (1) | EP3255042B1 (en) |
JP (1) | JP6615899B2 (en) |
KR (1) | KR101783642B1 (en) |
CN (1) | CN107250130B (en) |
AU (1) | AU2016216253B2 (en) |
BR (1) | BR112017016465B1 (en) |
CA (1) | CA2974788C (en) |
DK (1) | DK3255042T3 (en) |
ES (1) | ES2854707T3 (en) |
IL (1) | IL253538B (en) |
RU (1) | RU2710743C2 (en) |
SG (1) | SG11201705952SA (en) |
WO (1) | WO2016126085A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102444835B1 (en) | 2016-05-26 | 2022-09-19 | 리커리엄 아이피 홀딩스, 엘엘씨 | EGFR inhibitor compounds |
WO2020047518A1 (en) * | 2018-08-30 | 2020-03-05 | The Regents Of The University Of California | Ire1 kinase inhibitors and uses thereof |
CA3127958A1 (en) * | 2019-01-29 | 2020-08-06 | Beta Pharma, Inc. | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
KR102443873B1 (en) * | 2019-09-06 | 2022-09-19 | 비욘드바이오주식회사 | Process for Preparing Pyrimidinyl Bipyridine Compound and Intermediate Therefor |
KR20210029693A (en) | 2019-09-06 | 2021-03-16 | 비욘드바이오주식회사 | 2,6-Bis-(2-aminopyrimidin-4-yl)pyridin-3-ol dihydrochloride and pharmaceutical composition comprising the same |
WO2021045586A1 (en) * | 2019-09-06 | 2021-03-11 | 비욘드바이오주식회사 | 2'-amino-6-(2-amino-6-(1-isopropylpiperidin-4-yl)-5-methylpyrimidin-4-yl)-3'-fluoro-[2,4'-bipyridine]-5-ol 3-hydrochloride and pharmaceutical composition comprising same |
KR20210029694A (en) | 2019-09-06 | 2021-03-16 | 비욘드바이오주식회사 | 2'-Amino-6-(2-amino-6-methylpyrimidin-4-yl)-3'-fluoro-[2,4'-bipyridin]-5-ol dihydrochloride and pharmaceutical composition comprising the same |
US20230019999A1 (en) * | 2019-11-18 | 2023-01-19 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
CN111558044B (en) * | 2020-06-01 | 2022-02-11 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Pharmaceutical composition containing sunitinib, and preparation and application thereof |
CN116082310B (en) * | 2023-02-17 | 2024-08-20 | 厦门大学 | Bipyridine amide derivative, and preparation and application thereof |
CN116751195A (en) * | 2023-06-21 | 2023-09-15 | 杭州科兴生物化工有限公司 | Bipyridine compound, pharmaceutically acceptable salt thereof, preparation method and application |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
GB0013655D0 (en) * | 2000-06-05 | 2000-07-26 | Prolifix Ltd | Therapeutic compounds |
US6949571B2 (en) * | 2000-06-12 | 2005-09-27 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
JP2004534779A (en) * | 2001-05-30 | 2004-11-18 | エルジー ライフサイエンス リミテッド | Protein kinase inhibitors for disease treatment |
GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
WO2004016597A2 (en) * | 2002-08-14 | 2004-02-26 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
CN1742723A (en) | 2004-09-02 | 2006-03-08 | 天津倍方科技发展有限公司 | Medicine composition containing temozolomide-8-carboxylic ether and use of such compound for preparing anti-tumor medicine |
WO2008106202A1 (en) * | 2007-02-27 | 2008-09-04 | Housey Gerard M | Theramutein modulators |
WO2010018458A2 (en) * | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
-
2016
- 2016-02-02 EP EP16746826.3A patent/EP3255042B1/en active Active
- 2016-02-02 JP JP2017541860A patent/JP6615899B2/en active Active
- 2016-02-02 SG SG11201705952SA patent/SG11201705952SA/en unknown
- 2016-02-02 US US15/546,714 patent/US10227328B2/en active Active
- 2016-02-02 WO PCT/KR2016/001133 patent/WO2016126085A2/en active Application Filing
- 2016-02-02 DK DK16746826.3T patent/DK3255042T3/en active
- 2016-02-02 CN CN201680008749.8A patent/CN107250130B/en active Active
- 2016-02-02 BR BR112017016465-5A patent/BR112017016465B1/en active IP Right Grant
- 2016-02-02 RU RU2017130825A patent/RU2710743C2/en active
- 2016-02-02 ES ES16746826T patent/ES2854707T3/en active Active
- 2016-02-02 KR KR1020160013029A patent/KR101783642B1/en active IP Right Grant
- 2016-02-02 CA CA2974788A patent/CA2974788C/en active Active
- 2016-02-02 AU AU2016216253A patent/AU2016216253B2/en active Active
-
2017
- 2017-07-18 IL IL253538A patent/IL253538B/en active IP Right Grant
-
2019
- 2019-01-07 US US16/241,177 patent/US10611754B2/en active Active
-
2020
- 2020-02-21 US US16/798,134 patent/US20200190062A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ734084A (en) | 2023-09-29 |
US10227328B2 (en) | 2019-03-12 |
SG11201705952SA (en) | 2017-09-28 |
CN107250130A (en) | 2017-10-13 |
EP3255042A4 (en) | 2018-08-01 |
DK3255042T3 (en) | 2021-02-08 |
CN107250130B (en) | 2019-11-08 |
AU2016216253B2 (en) | 2019-11-21 |
RU2017130825A (en) | 2019-03-04 |
US10611754B2 (en) | 2020-04-07 |
AU2016216253A1 (en) | 2017-08-17 |
RU2710743C2 (en) | 2020-01-10 |
ES2854707T3 (en) | 2021-09-22 |
CA2974788C (en) | 2023-04-11 |
US20200190062A1 (en) | 2020-06-18 |
IL253538A0 (en) | 2017-09-28 |
JP6615899B2 (en) | 2019-12-04 |
BR112017016465B1 (en) | 2023-11-14 |
KR101783642B1 (en) | 2017-10-10 |
JP2018504449A (en) | 2018-02-15 |
KR20160096033A (en) | 2016-08-12 |
US20180273510A1 (en) | 2018-09-27 |
WO2016126085A3 (en) | 2016-11-03 |
EP3255042B1 (en) | 2020-12-30 |
EP3255042A2 (en) | 2017-12-13 |
RU2017130825A3 (en) | 2019-08-12 |
IL253538B (en) | 2020-09-30 |
WO2016126085A2 (en) | 2016-08-11 |
CA2974788A1 (en) | 2016-08-11 |
US20190135786A1 (en) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3256138T3 (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING MELOXICAM | |
DK3529248T3 (en) | Pharmaceutical compositions | |
DK3495023T3 (en) | SEMIFLUOROIATED COMPOUNDS AND COMPOSITIONS THEREOF | |
BR112017016465A2 (en) | heterocyclic compound and pharmaceutical composition comprising it | |
DK3357513T3 (en) | PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
BR112016015706A2 (en) | compound, use of it and pharmaceutical composition | |
DK3416996T3 (en) | HARDLY COMPOSITION | |
ES2796177T5 (en) | Pharmaceutical composition | |
DK3102200T3 (en) | Therapeutic compound and composition | |
DK3529240T3 (en) | Pharmaceutical compounds | |
DK3532029T3 (en) | Liquid pharmaceutical composition | |
DK3554534T3 (en) | PHARMACEUTICAL COMPOSITION INCLUDING INSULIN | |
DK3528902T3 (en) | RINGEGEL COMPOSITION | |
DK3275452T3 (en) | PHARMACEUTICAL COMPOSITION WITH SILIBININE | |
DK3583943T3 (en) | PHARMACEUTICAL COMPOSITION | |
DK3672948T3 (en) | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | |
PT3202759T (en) | Alpha-aminoamide derivative compound and pharmaceutical composition comprising same | |
DK3388085T3 (en) | PHARMACEUTICAL COMPOSITION AND USES THEREOF | |
DK3328368T3 (en) | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | |
DK3393254T3 (en) | COMPOSITION | |
DK3302483T3 (en) | PHARMACEUTICAL COMPOSITIONS AND APPLICATION THEREOF | |
DK3416502T3 (en) | GLYCEMIC-REDUCING COMPOSITION | |
DK3288933T3 (en) | OXINDOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
DK3357520T3 (en) | VISCOELASTIC COMPOSITION | |
DK3322295T3 (en) | COMPOSITION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2016, OBSERVADAS AS CONDICOES LEGAIS |